SHPG has been the topic of several other research reports. Goldman Sachs Group Inc. reissued a buy rating on shares of Shire PLC in a report on Tuesday, June 28th. Zacks Investment Research cut Shire PLC from a buy rating to a hold rating in a report on Wednesday, June 8th. HSBC cut Shire PLC from a buy rating to a hold rating in a report on Monday. Shore Capital reaffirmed a buy rating on shares of Shire PLC in a report on Tuesday, June 14th. Finally, Sanford C. Bernstein reaffirmed an outperform rating and issued a $222.00 price target on shares of Shire PLC in a report on Thursday, June 9th. Five equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $230.67.
Shares of Shire PLC (NASDAQ:SHPG) opened at 194.82 on Monday. The firm’s 50-day moving average price is $196.27 and its 200 day moving average price is $185.51. The stock has a market capitalization of $58.03 billion, a P/E ratio of 40.49 and a beta of 1.11. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.28 billion. During the same quarter in the previous year, the company earned $2.63 earnings per share. The firm’s quarterly revenue was up 55.9% compared to the same quarter last year. Analysts expect that Shire PLC will post $12.93 EPS for the current fiscal year.
The company also recently declared a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be issued a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 15.63%.
A number of large investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. purchased a new stake in Shire PLC during the second quarter worth about $5,561,000. Northwestern Mutual Wealth Management Co. boosted its stake in Shire PLC by 157.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,645 shares of the biopharmaceutical company’s stock worth $1,591,000 after buying an additional 5,293 shares during the period. Cowen Group Inc. purchased a new stake in Shire PLC during the second quarter worth about $920,000. Beacon Trust Co. purchased a new stake in Shire PLC during the second quarter worth about $2,643,000. Finally, IFP Advisors Inc boosted its stake in Shire PLC by 871.9% in the second quarter. IFP Advisors Inc now owns 2,702 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 2,424 shares during the period. Institutional investors own 24.26% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.